Extensions

Analysis of U.S. Patent 12,252,506: Term, Continuations, and Family Members

Washington, D.C. - A detailed analysis of U.S. Patent 12,252,506, titled "Methods of preparing nicotinamide riboside and derivatives thereof," reveals a complex prosecution history involving multiple continuing applications and a significant patent term adjustment. This patent is a key asset in the intellectual property portfolio of Niagen Bioscience, Inc.

Patent Term and Expiration:

U.S. Patent 12,252,506, which issued on March 18, 2025, has a projected expiration date of July 30, 2034. This date includes a Patent Term Adjustment (PTA). Generally, a U.S. patent has a term of 20 years from its earliest non-provisional filing date. However, this term can be extended to compensate for administrative delays by the U.S. Patent and Trademark Office (USPTO) during the examination process. No Patent Term Extension (PTE), which is typically granted for delays in regulatory review for products like pharmaceuticals, has been noted for this patent.

Continuation and Family History:

The application that matured into patent 12,252,506 (U.S. Application No. 18/307,733) is part of a long chain of continuing applications, demonstrating a strategy to build a robust patent portfolio around this technology. This indicates an ongoing effort to protect various aspects of the invention.

The lineage of this patent is as follows:

• It is a continuation of U.S. Application No. 17/736,834 (filed May 4, 2022).
• Which is a continuation of U.S. Application No. 16/886,985 (filed May 29, 2020), now U.S. Patent No. 11,584,770.
• Which is a continuation of U.S. Application No. 15/905,922 (filed February 27, 2018), now U.S. Patent No. 10,815,262.
• Which is a continuation of U.S. Application No. 14/908,831 (filed January 29, 2016), now U.S. Patent No. 10,000,519.

This chain of applications traces back to the international patent application PCT/EP2014/065971 (filed July 24, 2014), which itself claims priority from United Kingdom Patent Application No. 1313465.5 (filed July 29, 2013). This extensive family highlights the international scope of the patent protection strategy. No divisional applications were identified.

Related Family Members:

The broader patent family includes numerous corresponding patents and applications in various jurisdictions, reflecting the global commercial interest in nicotinamide riboside. Key family members include patents granted in Australia, Canada, China, Europe, Japan, and Korea. The extensive network of patents demonstrates a comprehensive effort to protect the technology in major markets worldwide.